RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCIE SCOPUS

      Increased Risk of Diabetes after Definitive Radiotherapy in Patients with Indolent Gastroduodenal Lymphoma

      한글로보기

      https://www.riss.kr/link?id=A107979874

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Purpose This study aimed to evaluate the effect of radiotherapy (RT) on the risk of diabetes by assessing hemoglobin A1c (HbA1c) levels in patients with gastroduodenal indolent lymphoma. Materials and Methods This retrospective study included patients...

      Purpose This study aimed to evaluate the effect of radiotherapy (RT) on the risk of diabetes by assessing hemoglobin A1c (HbA1c) levels in patients with gastroduodenal indolent lymphoma.
      Materials and Methods This retrospective study included patients with stage I extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue or follicular lymphoma of the gastroduodenal region who were treated with Helicobacter pylori eradication and/or RT between 2000 and 2019 in our institution. Of total 79 patients with HbA1c test, 17 patients received RT (RT group), while 62 patients did not receive RT (control group). A diabetes-associated event (DAE) was defined as a ≥ 0.5% increase in HbA1c levels from baseline, and diabetes event (DE) were defined as HbA1c level of ≥ 6.5%.
      Results During the median follow-up of 49 months, no local failure occurred after RT and no patients died of lymphoma. The RT group had significantly higher risk for DAEs on univariable analysis (hazard ratio [HR], 4.18; 95% confidence interval [CI], 1.64 to 10.66; p < 0.01) and multivariable analysis (HR, 3.68; 95% CI, 1.42 to 9.56; p=0.01). Further, the DE risk was significantly higher in the RT group than in the control group (HR, 4.32; 95% CI, 1.08 to 17.30; p=0.04) and in patients with increased baseline HbA1c levels (HR, 35.83; 95% CI, 2.80 to 459.19; p=0.01). On multivariable analysis, RT significantly increased the risk of DEs (HR, 4.55; 95% CI, 1.08 to 19.19; p=0.04), even after adjusting baseline HbA1c level (HR, 40.97; 95% CI, 3.06 to 548.01; p=0.01).
      Conclusion Patients who received RT for gastroduodenal indolent lymphoma had an increased risk of diabetes compared to those who did not.

      더보기

      다국어 초록 (Multilingual Abstract)

      Purpose This study aimed to evaluate the effect of radiotherapy (RT) on the risk of diabetes by assessing hemoglobin A1c (HbA1c) levels in patients with gastroduodenal indolent lymphoma.Materials and Methods This retrospective study included patients ...

      Purpose This study aimed to evaluate the effect of radiotherapy (RT) on the risk of diabetes by assessing hemoglobin A1c (HbA1c) levels in patients with gastroduodenal indolent lymphoma.Materials and Methods This retrospective study included patients with stage I extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue or follicular lymphoma of the gastroduodenal region who were treated with Helicobacter pylori eradication and/or RT between 2000 and 2019 in our institution. Of total 79 patients with HbA1c test, 17 patients received RT (RT group), while 62 patients did not receive RT (control group). A diabetes-associated event (DAE) was defined as a ≥ 0.5% increase in HbA1c levels from baseline, and diabetes event (DE) were defined as HbA1c level of ≥ 6.5%.Results During the median follow-up of 49 months, no local failure occurred after RT and no patients died of lymphoma. The RT group had significantly higher risk for DAEs on univariable analysis (hazard ratio [HR], 4.18; 95% confidence interval [CI], 1.64 to 10.66; p < 0.01) and multivariable analysis (HR, 3.68; 95% CI, 1.42 to 9.56; p=0.01). Further, the DE risk was significantly higher in the RT group than in the control group (HR, 4.32; 95% CI, 1.08 to 17.30; p=0.04) and in patients with increased baseline HbA1c levels (HR, 35.83; 95% CI, 2.80 to 459.19; p=0.01). On multivariable analysis, RT significantly increased the risk of DEs (HR, 4.55; 95% CI, 1.08 to 19.19; p=0.04), even after adjusting baseline HbA1c level (HR, 40.97; 95% CI, 3.06 to 548.01; p=0.01).Conclusion Patients who received RT for gastroduodenal indolent lymphoma had an increased risk of diabetes compared to those who did not.

      더보기

      참고문헌 (Reference)

      1 Marks LB, "Use of normal tissue complication probability models in the clinic" 76 (76): S10-S19, 2010

      2 Pinnix CC, "Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma" 39 : 1095-1100, 2017

      3 Sherwani SI, "Significance of HbA1c test in diagnosis and prognosis of diabetic patients" 11 : 95-104, 2016

      4 Gemici C, "Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer" 107 : 195-199, 2013

      5 van Nimwegen FA, "Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma" 32 : 3257-3263, 2014

      6 Groot HJ, "Risk of diabetes after para-aortic radiation for testicular cancer" 119 : 901-907, 2018

      7 Konig L, "Response rates and recurrence patterns after low-dose radiotherapy with 4Gy in patients with low-grade lymphomas" 194 : 454-461, 2018

      8 Giraud P, "Respiratory gating for radiotherapy : main technical aspects and clinical benefits" 97 : 847-856, 2010

      9 Wagman R, "Respiratory gating for liver tumors : use in dose escalation" 55 : 659-668, 2003

      10 Gunther JR, "Radiation therapy for salivary gland MALT lymphoma : ultra-low dose treatment achieves encouraging early outcomes and spares salivary function)" 61 : 171-175, 2020

      1 Marks LB, "Use of normal tissue complication probability models in the clinic" 76 (76): S10-S19, 2010

      2 Pinnix CC, "Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma" 39 : 1095-1100, 2017

      3 Sherwani SI, "Significance of HbA1c test in diagnosis and prognosis of diabetic patients" 11 : 95-104, 2016

      4 Gemici C, "Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer" 107 : 195-199, 2013

      5 van Nimwegen FA, "Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma" 32 : 3257-3263, 2014

      6 Groot HJ, "Risk of diabetes after para-aortic radiation for testicular cancer" 119 : 901-907, 2018

      7 Konig L, "Response rates and recurrence patterns after low-dose radiotherapy with 4Gy in patients with low-grade lymphomas" 194 : 454-461, 2018

      8 Giraud P, "Respiratory gating for radiotherapy : main technical aspects and clinical benefits" 97 : 847-856, 2010

      9 Wagman R, "Respiratory gating for liver tumors : use in dose escalation" 55 : 659-668, 2003

      10 Gunther JR, "Radiation therapy for salivary gland MALT lymphoma : ultra-low dose treatment achieves encouraging early outcomes and spares salivary function)" 61 : 171-175, 2020

      11 Harada A, "Radiation therapy for localized duodenal low-grade follicular lymphoma" 57 : 412-417, 2016

      12 de Vathaire F, "Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors : a retrospective cohort study" 13 : 1002-1010, 2012

      13 이한상 ; 오동렬 ; 양경미 ; 고영혜 ; 안용찬 ; 김원석 ; 김석진, "Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma" 대한암학회 51 (51): 547-555, 2019

      14 Pinnix CC, "Outcomes after reduced-dose intensity modulated radiation therapy for gastric mucosa-associated lymphoid tissue(MALT)lymphoma" 104 : 447-455, 2019

      15 Petersen JB, "Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours" 50 : 823-828, 2011

      16 Zelenetz AD, "NCCN guidelines insights: B-cell lymphomas, version 3.2019" 17 : 650-661, 2019

      17 Abbas H, "Motion management in gastrointestinal cancers" 5 : 223-235, 2014

      18 Yahalom J, "Modern radiation therapy for extranodal lymphomas : field and dose guidelines from the International Lymphoma Radiation Oncology Group" 92 : 11-31, 2015

      19 Zucca E, "Marginal zone lymphomas : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" 31 : 17-29, 2020

      20 Girinsky T, "Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma : a plausible approach? A single-institution experience in 10 patients" 83 : e385-e389, 2012

      21 Ruskone-Fourmestraux A, "Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma : Results of a prospective study with a long term follow-up" 117 : 178-182, 2015

      22 Meacham LR, "Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study" 169 : 1381-1388, 2009

      23 Kim SW, "Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma" 19 : 6062-6068, 2013

      24 Hoskin PJ, "4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma(FORT) : a randomised phase 3 non-inferiority trial" 15 : 457-463, 2014

      25 American Diabetes Association, "2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020" 43 (43): S14-S31, 2020

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2024 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2021-01-01 평가 등재학술지 선정 (해외등재 학술지 평가) KCI등재
      2020-12-01 평가 등재후보로 하락 (해외등재 학술지 평가) KCI등재후보
      2010-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2008-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2005-05-27 학술지명변경 한글명 : 대한암학회지 -> Cancer Research and Treatment KCI등재
      2005-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2004-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2002-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 3.58 0.89 3.01
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      2.62 2.28 1.846 0.26
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼